Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3 Garg et al. Garg et al. BMC Cancer 2014, 14:35 http://www.biomedcentral.com[removed]

Source URL: www.ncbi.nlm.nih.gov

• Mesothelin
• Proteins
• Drugs
• Immune system
• T cells
• Targeted therapy
• Bi-specific T-cell engager
• Apoptosis
• Fusion protein
• Biology
• Cell biology
• Monoclonal antibodies